Document is current

Article History

Received: 28 June 2024

Accepted: 18 November 2024

First Online: 23 December 2024

Declarations

:

: The ALFA + study (ALFA-FPM-0311) was approved by the Independent Ethics Committee “Parc de Salut Mar,” Barcelona, and registered at Clinicaltrials.gov (identifier: NCT02485730) on June 10, 2015. All participants signed the informed consent form that had also been approved by the Independent Ethics Committee “Parc de Salut Mar,” Barcelona. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments and comparable ethical standards.

: NA.

: H.Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). G.K. is a full‑time employee of Roche Diagnostics GmbH. C.Q.-R. is a full‑time employee of Roche Diagnostics International Ltd. O.G-R. has given lectures in symposia sponsored by Roche Diagnostics, and receives support for research (to the institution) from F- Hoffmann La Roche. M.S.-C. has given lectures in symposia sponsored by Roche Diagnostics, S.L.U, Roche Farma, S.A and Amirall. He has served as a consultant and at advisory boards for Roche Diagnostics International Ltd and Grifols S.L. He was granted with a project funded by Roche Diagnostics International Ltd; payments were made to the institution (BBRC). He received in-kind support for research (to the institution) from Roche Diagnostics International Ltd, Avid Radiopharmaceuticals, Inc., Eli Lilly and Janssen Research & Development.